Terms: = Germ cell tumor AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
215 results:
1. tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract] [Full Text] [Related]
2. The identification of BCL-XL and mcl-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.
Fitzgerald MC; O'Halloran PJ; Kerrane SA; Ní Chonghaile T; Connolly NMC; Murphy BM
Cell Death Dis; 2023 Oct; 14(10):705. PubMed ID: 37898609
[TBL] [Abstract] [Full Text] [Related]
3. Combined mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract] [Full Text] [Related]
4. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract] [Full Text] [Related]
5. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract] [Full Text] [Related]
6. Ponicidin Induces Apoptosis of Murine Melanoma by Inhibiting the NF-κB Signaling Pathway.
Wang L; Lou X; Wang D; Lu K; Zhang S; Cheng B
Biol Pharm Bull; 2023; 46(6):803-810. PubMed ID: 37258145
[TBL] [Abstract] [Full Text] [Related]
7. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
Richter S; Garrett TJ; Bechmann N; Clifton-Bligh RJ; Ghayee HK
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36897220
[TBL] [Abstract] [Full Text] [Related]
8. Survival Mechanisms of Metastatic Melanoma cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System.
Obrador E; Salvador-Palmer R; López-Blanch R; Oriol-Caballo M; Moreno-Murciano P; Estrela JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766760
[TBL] [Abstract] [Full Text] [Related]
9. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G-CSF in an autologous stem cell donor with testicular cancer.
Cooling L; Kelley J; Sexton E; Anand S; Hoffmann S
Transfusion; 2023 Apr; 63(4):684-689. PubMed ID: 36762622
[TBL] [Abstract] [Full Text] [Related]
10. IFN-γ Signaling Sensitizes Melanoma cells to BH3 Mimetics.
Ming Z; Lim SY; Stewart A; Pedersen B; Shklovskaya E; Menzies AM; Carlino MS; Kefford RF; Lee JH; Scolyer RA; Long GV; Rizos H
J Invest Dermatol; 2023 Jul; 143(7):1246-1256.e8. PubMed ID: 36736995
[TBL] [Abstract] [Full Text] [Related]
11. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and hlrcc-Associated Renal cell Carcinoma.
Ligon JA; Sundby RT; Wedekind MF; Arnaldez FI; Del Rivero J; Wiener L; Srinivasan R; Spencer M; Carbonell A; Lei H; Shern J; Steinberg SM; Figg WD; Peer CJ; Zimmerman S; Moraly J; Xu X; Fox S; Chan K; Barbato MI; Andresson T; Taylor N; Pacak K; Killian JK; Dombi E; Linehan WM; Miettinen M; Piekarz R; Helman LJ; Meltzer P; Widemann B; Glod J
Clin Cancer Res; 2023 Jan; 29(2):341-348. PubMed ID: 36302175
[TBL] [Abstract] [Full Text] [Related]
12. Repurposed Effect of
Elajami MK; Burton LP; Bahmad HF; Chaaya G; Schwartz M
Curr Oncol; 2022 Oct; 29(10):7552-7557. PubMed ID: 36290871
[TBL] [Abstract] [Full Text] [Related]
13. LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization.
Yin L; Liu X; Wu J; Yang J; Wang J; Dou H; Hou Y
Melanoma Res; 2022 Dec; 32(6):419-427. PubMed ID: 36094494
[TBL] [Abstract] [Full Text] [Related]
14. Pathological prognosis classification of patients with neuroblastoma using computational pathology analysis.
Liu Y; Jia Y; Hou C; Li N; Zhang N; Yan X; Yang L; Guo Y; Chen H; Li J; Hao Y; Liu J
Comput Biol Med; 2022 Oct; 149():105980. PubMed ID: 36001926
[TBL] [Abstract] [Full Text] [Related]
15. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics.
Koessinger AL; Cloix C; Koessinger D; Heiland DH; Bock FJ; Strathdee K; Kinch K; Martínez-Escardó L; Paul NR; Nixon C; Malviya G; Jackson MR; Campbell KJ; Stevenson K; Davis S; Elmasry Y; Ahmed A; O'Prey J; Ichim G; Schnell O; Stewart W; Blyth K; Ryan KM; Chalmers AJ; Norman JC; Tait SWG
Cell Death Differ; 2022 Oct; 29(10):2089-2104. PubMed ID: 35473984
[TBL] [Abstract] [Full Text] [Related]
16. Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma.
Nguyen TTT; Shang E; Schiffgens S; Torrini C; Shu C; Akman HO; Prabhu VV; Allen JE; Westhoff MA; Karpel-Massler G; Siegelin MD
Clin Cancer Res; 2022 May; 28(9):1881-1895. PubMed ID: 35417530
[TBL] [Abstract] [Full Text] [Related]
17. Brain-Targeted Codelivery of Bcl-2/Bcl-xl and mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy.
He W; Li X; Morsch M; Ismail M; Liu Y; Rehman FU; Zhang D; Wang Y; Zheng M; Chung R; Zou Y; Shi B
ACS Nano; 2022 Apr; 16(4):6293-6308. PubMed ID: 35353498
[TBL] [Abstract] [Full Text] [Related]
18. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract] [Full Text] [Related]
19. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.
Castro MV; Barbero GA; Máscolo P; Ramos R; Quezada MJ; Lopez-Bergami P
Cell Mol Biol Lett; 2022 Mar; 27(1):23. PubMed ID: 35260073
[TBL] [Abstract] [Full Text] [Related]
20. Synergism of a novel mcl‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.
Lee A; Jin HO; Masudul Haque M; Kim HY; Jung H; Park JH; Kim I; Song JY; Yoon HK; Kim HK; Han J; Park IC; Kim KS; Park SG
Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34913076
[TBL] [Abstract] [Full Text] [Related]
[Next]
